Dr. David Kerr

Endocrine Surgery

Senior Investigator, Diabetes Research and Digital Health Equity

United States of America

Publications

Selected publications from PubMed

Using molecular testing to improve the management of thyroid nodules with indeterminate cytology: an institutional experience with review of molecular alterations.

Glass RE, Marotti JD, Kerr DA, Levy JJ, Vaickus LJ, Gutmann EJ, Tafe LJ, Motanagh SA, Sorensen MJ, Davies L, Liu X

J Am Soc Cytopathol. 2022 Mar-Apr;11(2):79-86 doi: 10.1016/j.jasc.2021.08.004.

Noninvasive follicular thyroid neoplasm with papillary-like nuclear features reclassification and its impact on thyroid malignancy rate and treatment.

Mao ML, Joyal T, Picado O, Kerr D, Lew JI, Farrá JC

J Surg Res. 2018 Oct;230:47-52 doi: 10.1016/j.jss.2018.04.013.

Featured in

18 min

Could biomarkers in colorectal cancer help us to optimize adjuvant treatment?

Colorectal cancer patients may require adjuvant therapy depending on the biology and stage of the resected tumor. The ideal scenario is tailoring chemotherapy, obtaining the highest benefit. Use of the biomarker test provides robust data for clinical decision making, thereby delivering clinical benefits that improve patient outcomes and reduce healthcare costs. Prof David Kerr has devoted his career and experience to the study of biomarkers. In this lecture, he explains the process to validate the use of this test and its application in daily clinical practice.

Published

Apr 2015

Share this expert

Help your network discover Dr. David Kerr's clinical expertise.